View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
July 30, 2021updated 02 Sep 2021 2:27pm

Resumed trials remain level despite Delta variant dominance

The number of clinical trials resuming has remained the same since the beginning of the Covid-19 pandemic last year.

By GlobalData Healthcare

Since early March 2020, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due to the Covid-19 pandemic. Many companies have delayed the initiation of planned trials or withdrawn them completely and others have suspended enrollment in their ongoing trials or terminated the trials altogether. The majority of trial disruptions can be attributed to patient safety measures, strict lockdown requirements, social distancing procedures and the high demand on medical professionals to treat Covid-19 patients.

As the initial peak of the virus started declining, many trials were set to resume activity. However, the number of confirmed Covid-19 cases is increasing again due to the emergence of new variants.

The Covid-19 Dashboard on GlobalData’s Pharma Intelligence Center dynamically tracks both disrupted and resumed trials.

As of July 26, the number of resumed trials is currently at 1,054. Out of these trials, 57.3% are currently recruiting participants, 20.9% have completed recruitment but are still ongoing and 0.2% have yet to start recruiting subjects. Even though the general trend shows a gradual increase in the overall percentage of trials for each trial status, the biggest of which has been seen in ongoing, recruiting trials and ongoing, not recruiting trials, the number of overall trials has remained approximately the same.

The US has the highest number of resumed trials at 69.3%, followed by the UK at 9.3%, Spain at 7.5%, France at 7.1% and Germany at 6.8%.

Related Companies

Related Report
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena